Figure Legends
Fig. 1. Study population with comparison of skin prick test and
allergen-specific IgE measurement results between clinically confirmed
non-allergic controls and peanut allergic patients. (A) Blinded MONA
study serum samples (n=112) from the Toronto site with available
clinical status were transferred to the University of Bern. Serum
samples for which BAT data was recorded in MONAS (n=96) were included in
the clinical performance analysis of the Hoxb8 MAT and in direct
comparison to BAT. Amongst those SPT information for 47 samples and sIgE
measurements for 67 samples has been available. (B) Wheal size
measurement results from skin prick test compared between non-allergic
controls (NA; blue) and peanut allergic patients (PA; red). (C)
Comparison of allergen-specific IgE measurements by ImmunoCAP for peanut
extract, Ara h1, Ara h2, Ara h3, Ara h8 and Ara h9 between non-allergic
controls (NA; blue) and peanut allergic patients (PA; red). Data are
shown as individual data points and means ± SEMs. *P < 0.05,
****P < 0.001, ns = not significant.
Fig. 2. Performance analysis of Hoxb8 MAT and BAT to
differentiate between clinically confirmed non-allergic controls and
peanut allergic patients. Passively sensitized Hoxb8 MCs (A and B) or
whole blood (C and D) were stimulated with peanut allergen extract at
various doses (0-1000 ng/ml). Comparison of activated Hoxb8 MCs or blood
basophils in the non-allergic (NA) and peanut allergic (PA) group on a
population basis is shown (A and C). Dose-response curves of activated
Hoxb8 MCs and blood basophils for individual patient samples are
represented in two separate subpanels (B and D). Non-allergic controls
are depicted in blue, while peanut allergic patients are represented in
red. (E and F) ROC curve analyses for Hoxb8 MAT and BAT results across
different allergen concentrations (color coded) are depicted and AUROC
values are indicated. Data are shown as individual data points and means
± SEMs. *P < 0.05, ****P < 0.001.
Fig. 3. Correlation analysis between skin prick test or
allergen-specific IgE measurements and maximal activation signal in the
Hoxb8 MAT. Wheal size results from skin prick test (A) or allergen
specific IgE measurement for peanut extract (B), Ara h1 (C) and Ara h2
(D) from non-allergic controls (red dots) and allergic patients (blue
dots) were plotted against the maximal activation signal from the Hoxb8
MAT and a linear correlation analysis (red line) was performed. The
correlation coefficient (r) as well as the significance of the
correlation (p) are indicated for each subpanel.
Fig. 4. Analysis of seven BAT non-responder samples with the
Hoxb8 MAT. Seven sera from previously identified BAT non-responders
(NR1-7) were measured on passively sensitized Hoxb8 MCs. The clinically
confirmed allergy status of the individual patient samples is color
coded (peanut allergic, PA: red; non-allergic, NA: blue; no Information,
NI: orange).
Fig. 5. Direct comparison of performance analyses between
different diagnostic tests. Direct ROC curve analysis for SPT and sIgE
against peanut extract compared with ROC curve analysis of logistic
regression models with Hoxb8 MAT and BAT results including all peanut
allergen concentrations are depicted (color coded) and AUROC values are
indicated.